Kexrolt (Atorvastatin Calcium, Ezetimibe)

Atorvastatin calcium and ezetimibe, the active ingredient in Kexrolt, is a lipid‑lowering agent presented as a tablet for oral use. It provides additive reduction of LDL‑cholesterol in adults with primary hypercholesterolaemia, mixed dyslipidaemia, or heterozygous familial hypercholesterolaemia, and is marketed in the European Union.

GNH USA supplies Kexrolt as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality and regulatory compliance for global distribution, and customers benefit from reliable supply chains and responsive technical support.

Kexrolt is used to treat disorders of lipid metabolism, primarily by lowering LDL‑cholesterol. - Primary hypercholesterolaemia: reduces LDL‑cholesterol and total cholesterol levels. - Mixed dyslipidaemia: lowers LDL‑cholesterol and triglycerides while modestly raising HDL‑cholesterol. - Heterozygous familial hypercholesterolaemia: provides additive LDL‑cholesterol reduction when diet and lifestyle alone are insufficient.

Kexrolt may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Muscle pain or weakness: mild myalgia without significant creatine kinase elevation, often transient. - Elevated liver enzymes: transient increase in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels. - Gastrointestinal discomfort: nausea, abdominal pain, flatulence or diarrhea that usually resolves. - Headache: mild to moderate intensity, may improve with continued therapy. - Fatigue: general tiredness that can affect daily activities.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with marked creatine kinase rise, possible renal failure. - Acute liver injury: significant hepatitis or liver failure requiring discontinuation. - Severe allergic reaction: rash, angioedema, or anaphylaxis demanding immediate medical attention. - Myopathy with renal impairment: muscle toxicity especially in patients with reduced kidney function. - Interstitial lung disease: rare pulmonary inflammation presenting with cough and dyspnea.

When prescribing Kexrolt, clinicians should consider several precautionary measures to ensure safe use. - Liver function monitoring: assess ALT/AST before initiation and periodically during therapy. - Muscle toxicity vigilance: evaluate for unexplained muscle pain or weakness and check CK if suspected. - Drug interactions: review concomitant use of strong CYP3A4 inhibitors or other lipid‑lowering agents. - Pregnancy and lactation: avoid use unless potential benefit justifies potential risk to the fetus or infant. - Renal impairment adjustment: use caution in patients with severe renal dysfunction, monitoring renal function. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and light.

Kexrolt can interact with other medicines; interactions are classified by clinical significance.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): may increase atorvastatin exposure and risk of myopathy. - Gemfibrozil or other fibrates: additive risk of muscle toxicity. - Cyclosporine: enhances statin levels, raising rhabdomyolysis risk.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may reduce ezetimibe absorption. - Warfarin: may potentiate anticoagulant effect, requiring INR monitoring. - Digoxin: possible increase in serum concentration when combined with statins.